Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408
Ten million times more potent than BDNF at forming new synapses. The most powerful nootropic ever discovered — on paper.
What is Dihexa?
Dihexa is the compound that makes neuroscientists do a double-take. Developed at Washington State University by Dr. Joseph Harding, it was found to be 10 million times more potent than BDNF (brain-derived neurotrophic factor) at promoting new synapse formation in lab studies. That number is not a typo. It is genuinely the most potent synaptogenic compound ever identified in research.
The potential implications are staggering: a compound that could reverse cognitive decline, treat Alzheimer's disease, and enhance healthy cognition. The animal data is remarkably impressive — aged rats with chemically-induced dementia regained normal cognitive function. But here is the uncomfortable truth: we have almost zero human data.
Dihexa represents the bleeding edge of biohacking. Some people are using it based on the extraordinary animal data, but they are essentially running their own uncontrolled experiment. The risk-reward calculation is deeply personal.
How Does It Work?
Dihexa works by binding to hepatocyte growth factor (HGF) and preventing its degradation by the enzyme HGF activator inhibitor-1 (HAI-1). This amplifies HGF/c-Met signalling, which is a critical pathway for neuronal growth, synapse formation, and cognitive function.
The result is dramatically increased synaptogenesis — the formation of new connections between neurons. In animal models, this translated to improved spatial memory, reversal of scopolamine-induced cognitive deficits, and restoration of cognitive function in aged animals. It also crosses the blood-brain barrier when taken orally, which is unusual for peptide-derived compounds.
What Does The Research Say?
Limited evidence. Mostly animal studies and anecdotal reports.
The primary research comes from Dr. Harding's lab at WSU. Published studies show: reversal of cognitive deficits in rat models of dementia, promotion of new synapse formation at extraordinarily low concentrations, oral bioavailability, and blood-brain barrier penetration.
However — and this is crucial — there are no published human clinical trials. The compound was patented but never progressed through formal drug development. Everything we know about human effects comes from anecdotal self-experimentation in the biohacking community. Some report dramatic cognitive improvements; others report nothing. Without controlled human trials, we genuinely do not know the full safety or efficacy profile.
Reported Dosages
These are dosages reported in research literature and community reports. They are NOT medical recommendations. Always consult a healthcare professional.
No established human dose. Community reports typically use 10-20mg sublingually or orally, once daily.
Some reports use intranasal administration.
Cycles of 2-4 weeks are common in anecdotal protocols.
These are NOT evidence-based dosages — no human trials exist.
Side Effects & Risks
Unknown in humans with certainty. Anecdotal reports include: headache, jaw tension, vivid dreams, occasional anxiety. Theoretical concerns: uncontrolled synaptogenesis could theoretically promote seizures, and HGF pathway activation has theoretical cancer implications (HGF/c-Met signalling is overactive in some cancers).
Legal Status by Country
Not approved. Unregulated research chemical.
Not FDA-approved. Unregulated research chemical.
Not approved. Unregulated.
Not approved. Unregulated research chemical.
Important Disclaimer
This profile is for educational and research purposes only. It does not constitute medical advice. Dihexa may be regulated or illegal in your jurisdiction. Do not use any compound without consulting a qualified healthcare professional. StackPedia does not sell, supply, or promote the use of any controlled substance.